Trial Profile

RESOLUTE-III all-comers trial: A randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zotarolimus (Primary) ; Everolimus
Indications Coronary artery disease; Coronary artery restenosis
Focus Adverse reactions; Therapeutic Use
Acronyms RESOLUTE-All comers; RESOLUTE-III All comers
Sponsors Medtronic

Most Recent Events

05 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
31 Jan 2014 Results published in the Journal of the American College of Cardiology.
04 Nov 2013 Planned end date changed from 1 Dec 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com